CEO in UB-consulting AB, Uppsala, Sweden. Mr. Björklund is M.Sc. in Pharmacy with more than 30 years of experience from the pharmaceutical industry, which ranges from pharmaceutical discovery and development of new drugs to diagnostics - from research trough to marketing. Prior engagements include CEO of Aprea (oncology) and CEO of OxyPharma (autoimmune diseases). Before that he held several positions within Pharmacia covering clinical research in many therapeutic areas of which the majority of the time in managerial positions. Mr. Björklund has experience in managing partner collaborations, financing and dealing with regulatory authorities in Europe and US. Mr. Björklund is currently Chairman in Lipum AB and board member in TikoMed AB and Annexin Pharmaceuticals AB.
Per-Ola Forsberg has 20 years of experience in the pharmaceutical and biotech industry and has brought two companies to trading on Nasdaq. Per-Ola has held several CFO assignments, most recently at Idogen AB, before that at LIDDS AB, Lund University Bioscience AB and at Probi AB, where he also was executive vice CEO with business responsibility. His experience also includes positions as controller at Rexam Beverage Can Fosie AB and Head of Administration at PolyPeptide Laboratories AB, a subsidiary of Ferring AB. Per-Ola Forsberg holds a degree in Business and Economics from Lund University.
Appointed Professor in Experimental Pathology at the Medical Faculty, Lund University in 1996. Published more than 100 peer-reviewed papers on intracellular signaling, cell adhesion and migration. Co-founder of WntResearch in 2007 and has since held the position as CSO in the company. Tommy Andersson is inventor on the three patent families that form the basis for WntResearch. Previously, Tommy Andersson held an assistant professorship from the Swedish Research Council to work together with Professor Olle Stendahl at Linköping University and subsequently he obtained an independent associate professorship in cell biology at Linköping University until 1996 when recruited to Lund University. Professor Andersson’s research group has for many years obtained financial support from the Swedish Cancer Foundation and the Swedish Research Council as well as from numerous other foundations.
Dennis Henriksen joined Wntresearch in 2016. He has 20+ years managerial industry experience in small to medium size biotechnology companies, including several years in the United States as Vice President of BioNebraska Inc. where he also served as a member in the corporate management group and was responsible for R&D.
Key positions prior to joining Wntresearch include Vice President of Nordic Bioscience A/S, COO of Verigen Europe A/S, Vice President of Osteometer Biotech, Managing Director of BION, Vice President of BioNebraska and founder and CEO of Sanos Bioscience A/S from the formation of the company in 2003 until the company was sold in 2011.
Experienced in developing and implementing cGMP in small to medium size biotech companies and has been involved in research and development programs within the field of osteoporosis, arthritic diseases, inflammatory and autoimmune diseases, spinal cord injury, fungal infections and several forms of cancer.
Dennis Henriksen holds a M.Sc. in Chemical Engineering from the Technical University of Copenhagen and a Ph.D. in Bioorganic Chemistry from the University of Copenhagen.